Home
About Us
Company Introduction
Culture
Qualification
History
Related Enterprises
Products & Services
Pharmaceutical products
Pharmaceutical Raw Materials
Pharmaceutical intermediates
Customized services
CRO
CDMO
Innovation & Capability
Production Capacity
Technical Expertise
R&D Equipment
Quality & HSE Management
Quality Management
Quality Control
HSE Management
Blog
Industry News
Company News
Contact
Starting in September, these policies will affect doctors nationwide
07 Sep,2022
September, really is the point in time for the big changes in healthcare in 2017, recently I found that many of the heavy policies from the beginning of the year have been implemented this month, and if you didn't notice, you can only be just in the middle of the mountain.
Pharmaceutical API industry must change the traditional marketing model
With the gradual homogenization of the industry, as well as generic drug giveaway, in increasing the market demand for pharmaceutical APIs expanding at the same time, but also gradually appeared in the supply of pharmaceutical APIs in short supply, the offline retail model has been unable to meet the needs of the market.
Red and Yellow shares shrink, market value evaporates by $300 million What warning does it give to pharma?
Although the industrial field is far away, but the red and yellow blue in the crisis under the market performance, has been enough to let all the pharmaceutical enterprises to cause alarm: if the status quo of the low cost of violation of the law is not enough to make the pharmaceutical enterprises to enhance the awareness of the compliance of the operation, but due to the crisis of the incident of the performance of the market value as well as the impact of the enterprise's reputation is a fatal thing!
Offense or Defense? The pharmaceutical industry market is about to change dramatically
In 2018, China's pharmaceutical industry will usher in a decisive year of consistency evaluation. Whether it is the aggressive attacking faction or the defensive faction that chooses to retreat in the big wave, I believe that all of them have already smelled the shake-up that the unstoppable consistency evaluation is going to bring.
Year-End Stocktaking: A Review and Outlook of the New Health Care Reform Deal
12 Jul,2018
The current round of pharmaceutical new policies started in early 2015, although the drafting and issuance of the Environmental Protection Law is not by the drug regulatory authorities, but the impact on the pharmaceutical industry is the most serious ever.
Three Northeastern Provinces Jointly Promote "Two Vote System" for Drug Procurement
Liaoning, Jilin and Heilongjiang provinces have recently issued a joint notice to promote the "two-invoice system" for drug procurement by public medical institutions and to ensure a reduction in the workflow of drug production and operation enterprises.
2020 Edition of Chinese Pharmacopoeia to Improve Testing Programs for Traditional Chinese Medicine Standards
The National Pharmacopoeia Commission recently held a mini-conference on the preparation of the 2020 edition of the Chinese Pharmacopoeia. At the meeting, Zhang Wei, Secretary General of the National Pharmacopoeia Commission, said that the 2020 edition of the Pharmacopoeia will further consolidate and expand the achievements of the standardization of traditional Chinese medicine, improve the testing items of traditional Chinese medicine standards, comprehensively improve the safety and efficacy of traditional Chinese medicines, and continue to lead the development of international standards.
The State Council issued a document: the implementation of the action plan to improve the standards of drugs and medical devices!
Recently, the Guiding Opinions of the Central Committee of the Communist Party of China and the State Council on Carrying Out Quality Enhancement Actions (hereinafter referred to as the Guiding Opinions) was released.